Clinical trials: End Stage Disease
Kidney Failure, Chronic
Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate
- Trial name
- NCT00151931
- Testing
- Lanthanum carbonate
- Volunteers
- 456 people
- Sponsor
- Shire
Hepatocellular Carcinoma
Trial of TRC105 and Sorafenib in Patients With HCC
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma.
- Trial name
- NCT02560779
- Testing
- Carotuximab (TRC105), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Tracon Pharmaceuticals Inc.
End Stage Renal Disease (ESRD)
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).
- Trial name
- NCT03812679
- Testing
- AMIA APD Solution Generation System
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vantive Health LLC
ESRD (End Stage Renal Disease)
Fluid Status of Dialysis Subjects
The goal of this clinical pilot study is to evaluate the ability of the device to properly detect the hydration status of the subject through the study of fluid removal data during dialysis and HemoCept device data.
- Trial name
- NCT07217041
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HemoCept Inc.
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hypertension Emergency, End-organ Damage
Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients
To compare the efficacy and safety of two dose adjustment regimens (i.e. weight-based and non-weight-based) for the treatment of Chinese hypertensive emergency patients.
- Trial name
- NCT01872039
- Testing
- Perdipine injection
- Where
- 5 sites in China
- Volunteers
- 163 people
- Sponsor
- Astellas Pharma China, Inc.
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
Parkinson's Disease
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- 6002-009 (NCT00955526)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 373 people
- Sponsor
- Kyowa Kirin Co., Ltd.
End Stage Kidney Disease
Alio WEAR Study: Long-term Wear of the Alio Platform
The WEAR study is long-term interventional study designed to evaluate patient and clinician use of the Alio platform, per its FDA cleared indications.
- Trial name
- NCT06056739
- Testing
- Alio platform
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Alio, Inc.
Renal Failure Chronic Requiring Hemodialysis
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD)…
- Trial name
- CRUISE 1 (NCT01320202)
- Testing
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Heart Failure, Acute Coronary Syndromes
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）
The aim of the study is to evaluate diagnostic performance of N-terminal Brain natriuretic Peptide (NT-proBNP) in acute heart failure among Chinese population.
- Trial name
- NT-proBNP，HF (NCT06691477)
- Testing
- No Interventions
- Where
- 4 sites in China
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
CKD Anemia in Stable Dialysis Patients
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
- Trial name
- NCT02273726
- Testing
- Epoetin Alfa, Roxadustat
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 741 people
- Sponsor
- Kyntra Bio
Healthy
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered…
- Trial name
- NCT02412449
- Testing
- AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
Duchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function.
- Trial name
- NCT00847379
- Testing
- Ataluren
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 173 people
- Sponsor
- PTC Therapeutics
End-Stage Renal Disease
Cook Enforcer Post-Market Study
The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional…
- Trial name
- NCT03552289
- Testing
- Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- Cook Research Incorporated
Parkinson Disease
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval.
- Trial name
- NCT02248168
- Testing
- Pramipexole
- Volunteers
- 1,449 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on…
- Trial name
- NCT00646035
- Testing
- paricalcitol capsules
- Where
- 24 sites in United States, Poland
- Volunteers
- 75 people
- Sponsor
- Abbott
End-stage Renal Disease (ESRD)
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
- Trial name
- NCT02553889
- Testing
- ISIS 416858
- Where
- 8 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hyperphosphatemia, End Stage Renal Disease
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4 or 6 grams for 56 days, on…
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT01503736
- Testing
- ferric citrate
- Where
- 5 sites in Taiwan
- Volunteers
- 183 people
- Sponsor
- Panion & BF Biotech Inc.